Circ Arrhythm Electrophysiol. 2018;11:e006119. DOI: 10.1161/CIRCEP.117. 006119 May 2018 2 P ulmonary vein isolation (PVI) for atrial fibrillation (AF) improves long-term outcomes compared with antiarrhythmic drugs (AAD) but remains suboptimal particularly for persistent AF. [1] [2] [3] Unfortunately, attempts to improve outcomes by supplementing PVI with linear lesions or often extensive ablation of electrogram targets have had disappointing results. [2] [3] [4] Contemporary mapping shows that AF may be sustained by drivers, 5, 6 whose ablation may be promising. [7] [8] [9] This has been an increasingly popular area of interest, especially in the last 5 years, with increasing number of bench-tobedside studies and mostly small-sized, nonrandomized clinical studies with highly variable outcomes in terms of acute impact (AF termination), as well as long-term outcomes. In this study, our intention is to review all the published studies on AF driver ablation to provide some clarity over individual study results, about longterm clinical impact of this approach.
We, therefore, performed a systematic review and meta-analysis to assess the clinical impact of AF driver ablation. AF drivers are defined as electrically mappable mechanisms that sustain, rather than initiate, fibrillatory conduction. Several clinical mapping approaches have been used to reveal potential AF drivers, and we included studies of multiple AF mapping approaches reporting long-term outcomes. This includes dominant frequency analysis, 9 FIRM (Focal Impulse and Rotor Modulation), 7 and noncontact body surface mapping (ECVUE). 8 We also included recent studies mapping AF drivers using electrogram similarity 10 and dispersion 11 analyses. Our primary objective was to produce a pooled point estimate and confidence interval (CI) for success rates, defined as freedom from AF or freedom from any atrial arrhythmias at follow-up when AF driver ablation is added to PVI. Our secondary objectives included estimating (1) pooled point estimates and CIs for acute procedural outcomes of AF driver ablation when added to PVI and (2) meta-analysis of pooled results of AF driver ablation compared with a control group. The caveat is that most studies of AF driver ablation to date have been single-arm studies without control arms.
METHODS

Data Sources and Criteria for Selecting Studies
We searched MEDLINE (PubMed) and Cochrane databases (inception to August 1, 2017) using the terms atrial fibrillation
WHAT IS KNOWN?
• Contemporary mapping shows that atrial fibrillation (AF) may be sustained by drivers, whose ablation may be promising.
• Acute impact and long-term outcomes of AF driver ablation have been reported in small-sized, nonrandomized clinical studies with highly variable outcomes.
WHAT THE STUDY ADDS?
• This systematic review and meta-analysis provides a summary of currently available data on AF driver ablation and motivates further large multicenter randomized trials of AF driver ablation.
• AF driver ablation and pulmonary vein isolation, in a small number of controlled studies, seem to improve freedom from all arrhythmias compared with pulmonary vein isolation alone.
• Outcomes of single-arm studies are significantly limited by high heterogeneity. Figure 1 . When groups published multiple reports with overlapping cohorts, the most recent study was included. Definitions of an AF driver vary between studies, including consistent anatomic sites where rotational sites are anchored, 8 sites of consistent rotational activation, 7 sites of high dominant frequency, 9 and sites where dispersion of activation supports driver physiology. 11 For the purposes of this analysis, we included each of these studies that targeted ablation at these sites and assessed the long-term outcomes, using definitions used by the author of each study.
The systematic review was registered at PROSPERO (International Prospective Register of Systematic Reviews; CRD42017069091). Quality assessment was accomplished with the use of Delphi criteria for randomized studies and the Newcastle-Ottawa scale for nonrandomized studies by 3 reviewers (M.R., G.L.M., and M.A.; Table I in the Data  Supplement) . Agreement between all 3 reviewers was mandatory for the final classification of the studies.
The data used for the analyses (ie, published articles on AF driver ablation) are specifically referenced within the work and freely available to all researchers. Accordingly, we have not duplicated them. The analytic methods are described herein for other researchers to reproduce our results.
Data Extraction
Three authors (T.B., A.J.R., and G.L.M.) performed database searches independently with agreement on the inclusion of the selected trials. Data extraction and preparation of this article followed recommendations of the PRISMA group. 12 Data on demographics, comorbidities, procedural characteristics, and single-procedure outcomes were entered independently by 3 authors and reviewed for discrepancies. In studies permitting repeat ablations, short-and long-term outcomes for the first ablation were extracted. Procedural information collected included driver characteristics, acute AF termination rate, complication rate, fluoroscopy time, total ablation time, and total procedure duration.
Statistical Analysis
Continuous variables are presented as mean±SD. Nominal values are expressed as n (%). Analyses were performed using SPSS, version 19, and MedCalc, version 17.6. Data were pooled using random effects, using DerSimonian and Laird method. Statistical heterogeneity on each outcome of interest was quantified using the P value for the Q statistic and I 2 . Heterogeneity based on I 2 was considered low if <25%, moderate if 25% to 75%, and high if >75%. For pooling single arms, the pooled rate of freedom from AF along with freedom from both AF and atrial tachycardia (AT) was computed along with the 95% CI. For studies including a control group, the odds ratio (OR) and respective 95% CI were used to measure treatment effect. Meta-regression (using the unrestricted maximum likelihood method) was performed to compare associations of potentially confounding variables with the end point of freedom from AF and other arrhythmias.
RESULTS
Search Results
Initial search terms resulted in 202 studies that were retrieved for further analysis (Figure 1 ). Of these, 187 were excluded because they comprised duplicate populations, did not perform AF driver ablation or provide clinical outcomes with at least 6 months of mean follow-up duration, or were retracted, resulting in 15 studies. Another 2 studies were identified from review of bibliographies for a total of 17 studies. Table 1 presents the 17 studies included in this systematic review, comprised of 1 randomized controlled study, 3 nonrandomized controlled studies, and 13 studies with no control groups. [7] [8] [9] [10] [11] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Fifteen studies included cohorts that underwent AF driver ablation with PVI, 3 studies included cohorts with AF driver-only ablation, and 4 studies included control groups. Studies are displayed separately to show baseline information in each arm, and so, Atienza et al 9 is represented in 3 rows and Narayan et al, 7 Lin et al, 10 and Seitz et al 11 in 2 rows. The enrolled cohort of these studies comprises 3294 patients. Eight hundred sixty-six patients were treated with AF driver ablation in addition to PVI, 187 patients were treated with AF driver ablation without PVI, and 268 patients comprised the control populations. Ninety-one patients were exluded for various reasons (ie, intracardiac thrombus on transesophageal echocardiogram) after enrollment. Forty-seven patients who underwent ablation did not have long-term outcomes reported because of being lost to follow-up or inadequate follow-up duration. Sommer et al 13 and Haissaguerre et al 8 provided demographics and acute procedural data only for the control groups (n=1800 and n=82, respectively), without long-term outcomes. Details are reported separately in the Appendix in the Data Supplement.
Study Characteristics
The approaches used for mapping and ablation of AF drivers in each study are listed in Table 1 . PVI consisted of radiofrequency point-by-point lesions in all studies except for Rashid et al, 15 who used cryoballoon ablation in all patients, and Steinberg et al, 19 who used cryoballoon in first-time ablation patients but otherwise used point-by-point radiofrequency lesions. Beyond PVI, ablation strategies varied between reports. Narayan et al 7 and Tomassoni et al 14 included a left atrial roof line ablation in patients with persistent AF. Rashid et al 15 performed ablation of the cavotricuspid isthmus Table 1 Circ Arrhythm Electrophysiol. The final cohort included 75% patients with persistent or long-standing persistent AF and 25% with paroxysmal AF. Six studies consisted of patients with persistent and long-standing persistent AF only, whereas 9 studies contained a mixed cohort, and 1 study contained only patients with paroxysmal AF.
Mean follow-up duration was ≥12 months in 90% of the studies. All studies monitored patients using ECG or Holter monitoring at 3, 6, and 12 months. Across all articles, AF or AT recurrence was defined as arrhythmias lasting >30 seconds or >1% burden on implanted devices. AAD use was allowed at 1-year follow-up in 11 of the 17 (65%; Table II in the Data Supplement). Three studies 13, 16, 18 allowed AAD use only during the blanking period, and 1 study 10 did not clarify whether AAD use was allowed at 12-month follow-up. For this reason, we did not quantify results based on AAD use.
Role of AF Driver Ablation for Long-Term Freedom From AF and AF/AT
Studies With Control Groups
Summary of procedural details is listed in Table 2 7-11, 13 to
24
. Three studies (Narayan et al, 7 Atienza et al, 9 and In 3 controlled studies, the termination rates were reported for both driver ablation with PVI (n=129) and PVI alone (n=156). The pooled OR comparing these groups is 5.23 (CI, 1.97-13.93; P<0.01). Because of the small number of available series, attempts were not made to identify sources of heterogeneity using metaregression in these controlled studies, but differences among study characteristics that affect outcomes can be identified in Table III in the Data Supplement.
Pooling Single Arms
There were 15 studies where AF driver ablation was performed with PVI. Of these, 14 studies with 816 patients reported long-term freedom from AF. The pooled AF freedom was 72.5% (CI, 62.1-81.8; heterogeneity I 2 =90.0%; P<0.01). Fifteen studies with 837 patients reported long-term freedom from AF/AT. The pooled rate was 57.8% (CI, 47.5-67.7; I 2 =85.6%; P<0.01). The pooled results for freedom from AF and AF/AT are shown in Figure 3 . Three studies reported long-term outcomes with AF driver-only ablation, without PVI. Freedom from AF after driver only, reported in 177 patients in 3 studies, was 63.6% (CI, 25.5-94.8; I 2 =96.53%; P<0.01). 9, 11, 24 Freedom from AF/AT, reported in 150 patients in 2 studies, was 65.2% (CI, 44.4-83.4; I 2 =84.7%; P<0.01).
9,11
Of these 15 studies that reported outcomes on AF driver ablation with PVI, acute procedural outcomes were reported in n=865 patients. Figure 4 includes pooled acute termination rates of AF to sinus rhythm or AT as 39.6% (CI, 27.0-52.9; I 2 =92%; P<0.01) during AF driver ablation with PVI. In 3 studies (n=188) with AF driver ablation only, the termination rate was 64.5% (CI, 0.22-0.96; I 2 =97%; P<0.01). [7] [8] [9] [10] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Figure I in the Data Supplement reflects the pooled outcomes of AF driver ablation when added to PVI in 20 studies, when the outcomes of 5 abstracts presented in major meetings, including the abstract of the retracted manuscripts, are included.
Possible Sources of Heterogeneity, Risk of Bias Across Studies
Univariate meta-regression analysis was used to examine variables that may have impacted success rates in AF driver ablation with PVI, when potential confounder values were available. Results of the examined variables are presented in Table III in the Data Supplement. Larger left atrium size (P<0.01), longer ablation times (P<0.01), and termination or slowing of AF during ablation (P<0.01) were associated with greater freedom from AF, with larger study size showing a trend toward significance (P=0.08) in this direction. Heterogeneity was largely driven by 2 series 18, 19 that lay outside of the funnel plot of all series and reported lower success rates than expected for their sample sizes ( Figure II in the Data Supplement). On sensitivity analysis, exclusion of these 2 series yielded a pooled estimate of 78.3% AF freedom (CI, 72.59-83.47; I 2 =67.9%; P<0.01). Larger left atrium size also related to freedom from AF/AT (P<0.01), with longer follow-up duration trended to show lower rates of AF/AT freedom (P=0.05).
DISCUSSION
We performed a systematic review and meta-analysis of studies on AF driver ablation as an approach to improve the success of PVI or as a stand-alone ablation strategy in some studies. In the limited number of controlled Table demonstrates pooled odds ratio (OR) for freedom from atrial fibrillation (AF). Bottom, Table demonstrates pooled OR for freedom from AF/atrial tachycardia (AT) of 3 studies with driver ablation with pulmonary vein isolation (PVI) and 2 studies with driver-only ablation, compared with PVI. The study by Atienza et al 9 is represented in 2 rows to reflect driver ablation with PVI and driver-only ablation cohorts. CI indicates confidence interval.
Circ Arrhythm Electrophysiol. studies, AF driver ablation may offer greater arrhythmia freedom over conventional ablation alone, with acceptable heterogeneity in the analyses of freedom from AF/ AT. Single-arm studies were characterized by substantial heterogeneity. In a single-arm analysis of all studies, AF driver ablation with PVI produced a single-procedure freedom from AF of 72.5% and freedom from all arrhythmias of 57.8% freedom from all arrhythmias in a population of 75% with nonparoxysmal AF. Despite the limitations of included studies, several notable features are evident from this meta-analysis. First, targeted AF driver ablation as a stand-alone pro- cedure or when added to PVI may increase acute procedural termination of AF over PVI alone. It remains to be determined whether this supports the mechanistic importance of drivers, but AF termination in this analysis was associated with increased long-term arrhythmia freedom. Second, heterogeneity in long-term outcomes was substantial but driven by poor outcomes in 2 studies 18, 19 that lay outside the funnel plot, with lower results than expected by their sample sizes. Sensitivity analysis removing these 2 studies yielded low heterogeneity. The reasons for this remain unclear. Third, AF driver ablation seems to produce more favorable results when combined with conventional ablation (PVI) compared with studies in which it was used alone. It is unclear whether this reflects the cumulative effect of eliminating concomitant triggers by PVI, eliminating additional drivers by PVI, or some atrial debulking effect of greater ablation area.
Interest in human AF drivers is motivated by their potential to improve ablation beyond PVI alone, 2,26 based on mechanisms translated from optical mapping of human AF, 6 AF in animal studies, 5 and modeling studies. The challenge is that this translation has been at times unclear, with mixed acute results of AF driver ablation and varying long-term data as quantified in this systematic review and meta-analysis. Fundamental debate still exists on the mechanisms of human AF. Although many studies show localized AF rotational or focal drivers by many methods listed in this article, historical AF mapping studies show disorganized waves with no (or few) drivers. 27 Some studies have also shown drivers that may be unstable 28, 29 and hence less amenable to ablation. It remains undetermined whether conflicting results reflect patient selection, mapping methodology in AF, or other factors. Some data suggest that multiple mapping approaches may produce similar results when applied to the same patients, 30 but further studies are needed to understand these discrepancies. Studies included in this systematic review were insufficiently powered to compare outcomes between different AF mapping approaches.
Limitations
This study has limitations. The quality of evidence is moderate with only 1 randomized controlled trial meet- One major limitation is that ablation approach was heterogeneous between component trials, as is true for many ablation strategies for AF. We have tried to clarify in depth the differences in ablation approaches in the Data Supplement. Especially controlled studies in this meta-analysis had variable procedures in the control limb (ie, additional lines, complex fractionated atrial electrogram, posterior wall ablation), although this has been a feature of many randomized trials of PVI ablation. As with all meta-analyses, the statistical analysis was limited by variable reporting of follow-up, AAD, and other factors in each parent article. The control cohorts were also limited in number, with a slightly lower rate of redo ablation (25%-30% versus 35%-40%) that was not statistically significant. Redo ablation also did not predict freedom from AF or AF/AT in metaregression analyses (Table III in the Data Supplement) .
It was not always clearly stated in successive articles by the same authors whether the same subjects were used as in prior studies. We took a diligent and conservative approach to avoid including duplicate subjects. For this reason, the study by Miller et al 20 using FIRM was not analyzed because it included patients subsequently presented in the study by Buch et al, 18 Miller et al, 25 and Steinberg et al 19 who are analyzed separately. We did not include the article by Gianni et al 31 because it reported <6 months of follow-up, nor did we include its earlier abstract report or related retracted article in which this limb was described as 30 consecutive nonrandomized patients. 32 Studies such as those by Narayan et al 33, 34 and Baykaner et al 35 were also not included because these substudies reflected subjects who were included in earlier included studies. 7 Finally, we acknowledge that heterogeneity was high. However, this may be part of the landscape of emerging questions for which study outcomes are heterogeneous, as noted by Higgins et al, 36 in which ≈25% of meta-analyses in Cochrane Database had I 2 values of >50%, or by a few smaller studies which amplified this heterogeneity.
Conclusions
This systematic review and meta-analysis supports the possible benefit of a combined approach of AF driver ablation and PVI in improving freedom from all arrhythmias compared with conventional ablation alone. Outcomes of single-arm studies were significantly limited by high heterogeneity. This systematic review and meta-analysis provides a summary of currently available data on AF driver ablation and motivates further large multicenter randomized trials of AF driver ablation.
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